Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
The Lancet. Oncology
Shaw, Alice T AT; Felip, Enriqueta E; Bauer, Todd M TM; Besse, Benjamin B; Navarro, Alejandro A; Postel-Vinay, Sophie S; Gainor, Justin F JF; Johnson, Melissa M; Dietrich, Jorg J; James, Leonard P LP; Clancy, Jill S JS; Chen, Joseph J; Martini, Jean-François JF; Abbattista, Antonello A; Solomon, Benjamin J BJ